Month: March 2022

SAMPO PLC                 STOCK EXCHANGE RELEASE         14/03/2022 at 08:30 am Sampo plc’s share buybacks 11/03/2022 On 11/03/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  9,311 41.49 AQEU  9,870 41.67 CEUX  4,673 41.50 TQEX  88,727 41.60 XHELTOTAL 112,581 41.59  *rounded to two decimals                 On 1 October 2021, Sampo announced a share buyback programme of up to a maximum of EUR 750 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 4 October 2021, is...

Oslo, 14 March 2022 – DNO ASA, the Norwegian oil and gas operator, today announced that the Company’s shares will be traded ex-dividend effective 14 March 2022. A dividend payment of NOK 0.20 per share will be made on or about 21 March to all shareholders of record as of 15 March 2022. – For further information, please contact:Media: media@dno.noInvestors: investor.relations@dno.no – DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading...

Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancerAMEERA-3 trial did not meet primary endpoint of improving progression-free survival Ongoing trials continue as planned, including AMEERA-5 and AMEERA-6Paris, March 14, 2022. The Phase 2 AMEERA-3 clinical trial evaluating amcenestrant, an investigational optimized oral selective estrogen receptor degrader (SERD), did not meet its primary endpoint of improving progression-free survival (PFS) as assessed by an independent central review. The trial evaluated amcenestrant as monotherapy compared to endocrine treatment of physician’s choice in patients with locally advanced or metastatic estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer who progressed on or after hormonal...

TORONTO, March 13, 2022 (GLOBE NEWSWIRE) — Media Central Corporation (CSE: FLYY, FSE:3AT) or (the “Company”) announced today that it continues to defend itself against a civil claim brought by a former employee dating back to July 2020. The company filed a Form 2 response to Moore, Laura versus Vancouver Free Press Publishing DBA Georgia Straight on September 2, 2020. The company has declined on two occasions to settle the $250,000 claim. The next hearing is scheduled on May 3 and 4, 2022. About Media Central Corporation Inc. Media Central Corporation Inc. is an alternative media company situated to acquire and develop high-quality publishing assets starting with the recent acquisition of Vancouver Free Press Corp., the purchase of NOW Communications Inc. and the launch of digital cannabis platform CannCentral.com and ESports...

TORONTO, March 13, 2022 (GLOBE NEWSWIRE) — Media Central Corporation, Inc. (CSE: FLYY, FSE:3AT) or (the “Company”) today announced that on March 9, 2022 under section 244(1) of the Bankruptcy and Insolvency Act (Canada), Wei Lin in his capacity as Nominee Holder (the “Nominee Holder”) in respect to the Secured Convertible Debentures (the “Debentures”) issued on behalf of each of the holders (the “Debenture Holders”) of the Debentures outstanding in the aggregate principal amount of more than $1,097,000 intends to enforce its security against the property of the Company. The Debenture Holders have a general security interest in the assets of the Company pursuant to the terms of the Debentures. The Nominee Holder was appointed by the Debenture Holders holding more than 51% of the principal amount of the outstanding Debentures. The...

Children with three copies of SMN2 treated presymptomatically achieved age-appropriate milestones, including standing and walking; required no ventilatory or feeding tube support; and had no serious, treatment-related adverse eventsPost-hoc analyses of START, STR1VE-EU and STR1VE-US indicated children with SMA Type 1 achieved or maintained important measures of bulbar functionMore than 1,800 patients have now been treated with Zolgensma globally across clinical trials, managed access programs and in the commercial setting1Basel, March 13, 2022 — Novartis today announced new data that reinforce the transformational benefit of Zolgensma® (onasemnogene abeparvovec), an essential one-time treatment for spinal muscular atrophy (SMA). The completed Phase 3 SPR1NT study demonstrated that children with three copies of the SMN2 back-up...

ARLINGTON, Va., March 13, 2022 (GLOBE NEWSWIRE) — WTW, a leading global advisory, broking and solutions company, today announced it will withdraw from all of its businesses in Russia. Carl Hess, WTW’s CEO, said, “We continue to be dismayed by the crisis in Ukraine. WTW remains steadfast in our support for all our colleagues and their families in the region who have been affected. We wholeheartedly wish for a peaceful solution. WTW intends to transfer ownership of our Russian businesses to local management who will operate independently in the Russian market. While we strongly believe this is the right decision, it was not made in haste nor without consideration for our dedicated Russian colleagues.” About WTWAt WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging...

A single intravenous dose of NeuBase’s Myotonic Dystrophy Type 1 (DM1) development candidate, NT-0231.F, potently rescues splicing, restores chloride channel (Clcn1) function, and durably reverses myotonia in the HSALR model Multiple subcutaneous doses also lead to molecular and functional rescue in the HSALR model demonstrating efficacy in a dose-dependent manner and potential feasibility of this patient-friendly administration route Company remains on track to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in 4Q CY2022 NeuBase management to host a conference call and webcast tomorrow, March 14, at 8:00 a.m. EDTPITTSBURGH and CAMBRIDGE, Mass., March 13, 2022 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”),...

–  For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value 600 mg/day of calcium supplements) with no increase in prescribed study drug within the 4 weeks prior to the Week 26 visit – was achieved by 78.7% of TransCon PTH-treated patients (48 of 61), compared to 4.8% for patients (1 of 21) in control group (p-value

Oslo, 13 March 2022: The CEO of Belships ASA (“the Company”), Lars Christian Skarsgård, has today exercised all his 5,000,000 options in the Company against cash settlement by the Company. The share options were granted to Skarsgård when he was appointed as the new CEO of the Company in 2019. The amount payable per share is equal to NOK 18,64 (equal to the VWAP of the share the last 10 business days prior to settlement) less the strike price of NOK 4.10. Furthermore, the board of directors of the Company has decided to grant Skarsgård 5,000,000 new options to subscribe for up to 5,000,000 shares in the Company with an exercise price of NOK 18.64 per share. The options can be exercised in the period between 36 months and 60 months from the date of grant. The company may honour exercised options by delivery of new shares in...